Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunotherapy and gene therapy

B J Gitlitz¹, A Belldegrun, R A Figlin

¹Department of Internal Medicine, University of California Los Angeles School of Medicine 90095-7059, USA.

Seminars in Urologic Oncology

|November 1, 1996

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

British journal of cancer·2017

Same author

T-cell recruitment: a tool for specific immunosuppression.

Immunology today·2014

Same author

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2014

Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014

Interleukin-2 (IL-2) immunotherapy offers durable remissions for some metastatic renal cell carcinoma (RCC) patients. This treatment is recommended for patients with good performance status and no severe heart or lung issues.

Area of Science:

Oncology
Immunotherapy

Background:

Metastatic renal cell carcinoma (RCC) is largely chemoresistant.
Immunotherapy, including interleukin-2 (IL-2) and interferon alfa (IFN-alpha), is a primary treatment modality for RCC.
Novel approaches like gene therapy are also being explored.

Purpose of the Study:

To review the role of interleukin-2 (IL-2) as a treatment option for metastatic renal cell carcinoma (RCC).
To identify patient populations that may benefit most from IL-2 therapy.

Main Methods:

Review of current treatment options for metastatic renal cell carcinoma.
Focus on immunotherapy, specifically IL-2.
Analysis of IL-2 efficacy and patient selection criteria.

Main Results:

Related Experiment Videos

Interleukin-2 (IL-2) is an FDA-approved biological agent for metastatic RCC.
IL-2 can induce durable remissions in a subset of patients.
Patients with good performance status and no significant cardiac or pulmonary comorbidities are suitable candidates.

Conclusions:

IL-2-based immunotherapy is a viable first-line treatment for selected metastatic RCC patients.
Careful patient selection is crucial for optimizing outcomes with IL-2 therapy.